Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

A recombinant triplebody with specificity for CD19 and HLA-DR mediates 
preferential binding to antigen double-positive cells by dual-targeting

(2012) Ingo Schubert et al.   mAbs

Preclinical studies on targeted delivery of multiple IFN 2b to HLA-DR in diverse hematologic cancers

(2011) E. A. Rossi et al.   BLOOD

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

(2010) R. Stein et al.   BLOOD

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

(2010) Thomas S. Lin et al.   LEUKEMIA & LYMPHOMA

Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma

(2010) Rhona Stein et al.   LEUKEMIA & LYMPHOMA

The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange

(2009) Kerrin Hansen et al.   MOLECULAR IMMUNOLOGY

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

(2009) Aran F Labrijn et al.   NATURE BIOTECHNOLOGY